含HIV蛋白酶抑制剂的抗逆转录病毒治疗通过损害成骨细胞分化和骨质量增加骨折风险
长期抗逆转录病毒治疗与骨折风险增加相关,但机制不明。研究检测了含蛋白酶抑制剂(PI)或整合酶链转移抑制剂(INSTI)方案治疗HIV感染者的血清羧化不全骨钙素和戊糖苷(骨质量差的标志物),发现PI治疗者两者显著升高,换用INSTI后显著下降;PI处理小鼠骨力学性能受损且羧化不全骨钙素更高,成骨细胞分化受抑。
要点
- PI方案治疗者血清羧化不全骨钙素和戊糖苷显著高于INSTI方案者。
- 换用INSTI可显著降低上述骨质量差标志物。
- PI通过抑制成骨细胞分化损害骨质量,增加骨折风险。
核心结论
- 含PI的抗逆转录病毒治疗对骨质量有不良影响,并抑制成骨细胞分化。
研究设计与样本
- 在HIV感染者中比较PI方案与含整合酶链转移抑制剂方案治疗者的血清标志物,并结合PI处理小鼠和成骨细胞实验。
主要发现
- PI治疗患者血清羧化不全骨钙素和戊糖苷显著高于INSTI治疗者。
- 换用INSTI后血清羧化不全骨钙素和戊糖苷显著下降。
- PI处理小鼠骨力学性能受损且羧化不全骨钙素水平更高。
- PI处理成骨细胞分化受抑。
临床怎么用
- 对接受含PI方案治疗的HIV感染者应关注骨质量与骨折风险。
- 考虑换用含INSTI方案可能改善骨质量标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-term antiretroviral therapy is associated with increased fracture risk, but the mechanism remains elusive. We measured serum undercarboxylated osteocalcin and pentosidine (markers of poor bone quality) in human immunodeficiency virus-infected patients treated with protease inhibitors (PIs) or an integrase strand transfer inhibitor-containing regimen. The results demonstrated significantly higher undercarboxylated osteocalcin and pentosidine in PI-treated patients. Switching to integrase strand transfer inhibitor significant decreased these markers. We also showed impaired bone mechanical properties with higher undercarboxylated osteocalcin level in PI-treated mice and inhibited osteoblast differentiation in PI-treated osteogenic cells. The results confirmed the adverse effects of PIs on bone quality and osteoblast differentiation.
引用
- Hirakawa H, Gatanaga H, Ochi H, et al. Antiretroviral Therapy Containing HIV Protease Inhibitors Enhances Fracture Risk by Impairing Osteoblast Differentiation and Bone Quality. J Infect Dis. 2017. PMID: 28525596. doi:10.1093/infdis/jix246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。